Division of Surgical Oncology, Department of Surgery, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, Florida.
Department of Surgery, Vanderbilt University School of Medicine, Nashville, Tennessee.
Gastroenterology. 2015 Dec;149(7):1932-1943.e9. doi: 10.1053/j.gastro.2015.07.058. Epub 2015 Aug 7.
BACKGROUND & AIMS: A hallmark of pancreatic ductal adenocarcinoma (PDAC) is the presence of a dense desmoplastic reaction (stroma) that impedes drug delivery to the tumor. Attempts to deplete the tumor stroma have resulted in formation of more aggressive tumors. We have identified signal transducer and activator of transcription (STAT) 3 as a biomarker of resistance to cytotoxic and molecularly targeted therapy in PDAC. The purpose of this study is to investigate the effects of targeting STAT3 on the PDAC stroma and on therapeutic resistance.
Activated STAT3 protein expression was determined in human pancreatic tissues and tumor cell lines. In vivo effects of AZD1480, a JAK/STAT3 inhibitor, gemcitabine or the combination were determined in Ptf1a(cre/+);LSL-Kras(G12D/+);Tgfbr2(flox/flox) (PKT) mice and in orthotopic tumor xenografts. Drug delivery was analyzed by matrix-assisted laser desorption/ionization imaging mass spectrometry. Collagen second harmonic generation imaging quantified tumor collagen alignment and density.
STAT3 activation correlates with decreased survival and advanced tumor stage in patients with PDAC. STAT3 inhibition combined with gemcitabine significantly inhibits tumor growth in both an orthotopic and the PKT mouse model of PDAC. This combined therapy attenuates in vivo expression of SPARC, increases microvessel density, and enhances drug delivery to the tumor without depletion of stromal collagen or hyaluronan. Instead, the PDAC tumors demonstrate vascular normalization, remodeling of the tumor stroma, and down-regulation of cytidine deaminase.
Targeted inhibition of STAT3 combined with gemcitabine enhances in vivo drug delivery and therapeutic response in PDAC. These effects occur through tumor stromal remodeling and down-regulation of cytidine deaminase without depletion of tumor stromal content.
胰腺导管腺癌 (PDAC) 的一个显著特征是存在致密的促结缔组织增生反应 (基质),这会阻碍药物输送至肿瘤。尝试耗尽肿瘤基质会导致肿瘤变得更具侵袭性。我们已经确定信号转导子和转录激活子 (STAT) 3 是 PDAC 中对细胞毒性和分子靶向治疗产生耐药性的生物标志物。本研究旨在研究针对 STAT3 对 PDAC 基质和治疗抵抗的影响。
在人胰腺组织和肿瘤细胞系中测定激活的 STAT3 蛋白表达。在 Ptf1a(cre/+);LSL-Kras(G12D/+);Tgfbr2(flox/flox) (PKT) 小鼠和原位肿瘤异种移植模型中,测定 JAK/STAT3 抑制剂 AZD1480、吉西他滨或联合用药的体内作用。通过基质辅助激光解吸/电离成像质谱分析药物输送。胶原二次谐波产生成像定量分析肿瘤胶原排列和密度。
STAT3 激活与 PDAC 患者的生存率降低和晚期肿瘤分期相关。STAT3 抑制联合吉西他滨显著抑制 PDAC 的原位和 PKT 小鼠模型中的肿瘤生长。这种联合治疗可减弱 SPARC 的体内表达,增加微血管密度,并增强药物输送至肿瘤,而不会耗尽基质胶原或透明质酸。相反,PDAC 肿瘤表现出血管正常化、肿瘤基质重塑以及胞苷脱氨酶下调。
靶向抑制 STAT3 联合吉西他滨可增强 PDAC 中的体内药物输送和治疗反应。这些作用是通过肿瘤基质重塑和下调胞苷脱氨酶实现的,而不会耗尽肿瘤基质含量。